BRIEF-NexPoint Residential Trust Q3 Core FFO Per Share Basic USD 0.52
Reuters2026/11/03 13:16Nov 03 (Reuters) - NexPoint Residential Trust Q3 FFO USD 11.653 million.
- Q3 net income USD -11.532 million
- Q3 FFO per share basic USD 0.46
- Q3 core FFO USD 13.366 million
- Q3 revenue USD 64.5 million vs. IBES estimate USD 64.4 million
- Q3 EPS USD -0.45
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
